The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 25, 2014

Filed:

Jun. 09, 2011
Applicants:

Karen Briner, Indianapolis, IN (US);

Manuel Javier Cases-thomas, Reading, GB;

Marta Adeva Bartolome, Madrid, ES;

Christopher Stanley Galka, Carmel, IN (US);

Alicia Marcos Llorente, Madrid, ES;

Maria Angeles Martinez-grau, Madrid, ES;

Michael Philip Mazanetz, Abingdon, GB;

John Cunningham O'toole, Indianapolis, IN (US);

Richard Edmund Rathmell, Hampshire, GB;

Matthew Robert Reinhard, Indianapolis, IN (US);

Selma Sapmaz, Basingstoke, GB;

Andrew Caerwyn Williams, Hampshire, GB;

Inventors:

Karen Briner, Indianapolis, IN (US);

Manuel Javier Cases-Thomas, Reading, GB;

Marta Adeva Bartolome, Madrid, ES;

Christopher Stanley Galka, Carmel, IN (US);

Alicia Marcos Llorente, Madrid, ES;

Maria Angeles Martinez-Grau, Madrid, ES;

Michael Philip Mazanetz, Abingdon, GB;

John Cunningham O'Toole, Indianapolis, IN (US);

Richard Edmund Rathmell, Hampshire, GB;

Matthew Robert Reinhard, Indianapolis, IN (US);

Selma Sapmaz, Basingstoke, GB;

Andrew Caerwyn Williams, Hampshire, GB;

Assignee:

Eli Lilly and Company, Indianapolis, IN (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/55 (2006.01); C07D 223/16 (2006.01); C07D 401/12 (2006.01); C07D 403/12 (2006.01); C07D 409/12 (2006.01); C07D 417/12 (2006.01);
U.S. Cl.
CPC ...
Abstract

The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula (I) as selective 5-HT2c receptor agonists for the treatment of 5-HT2c associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety, where, R6 is —NR10R11, where R10 is substituted phenylalkyl or substituted pyridylalkyl and other substituents are as defined in the specification.


Find Patent Forward Citations

Loading…